Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype

Stephen M. Wiesner, Jennifer L. Geurts, Miechaleen D. Diers, Rachel J. Bergerson, Diane E. Hasz, Kelly J. Morgan, David A. Largaespada

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Juvenile Myelomonocytic Leukemia (JMML) is a relentlessly progressive myeloproliferative/myelodysplastic (MPD/MDS) hematopoietic disorder more common in patients with any one of at least three distinct genetic lesions, specifically NF1 gene loss and PTPN11 and NRAS mutations. NF1 and PTPN11 are molecular lesions associated with Neurofibromatosis Syndrome Type I (NF1 Syndrome) and Noonan's Syndrome, respectively. The occurrence of JMML is rare; even among those predisposed with these syndromes to development of disease, and secondary genetic events likely contribute to the development and progression of disease. In NF1 syndrome, loss of p53 function is a common event in solid tumors, but uncommon in JMML, suggesting that the p53 pathway may be modified by other events in this hematopoietic disorder. The work presented here investigates the possible role of the p19Arf (p19) tumor suppressor in development of MPD associated with Nf1 gene loss in mice. We find that Nf1 mutant hematopoietic cells with loss of p19 develop accelerated hematopoietic disease similar to acute leukemia with a variable phenotype. This suggests that p19 may play a role in development of JMML and evaluation of the human p19 homolog (p14ARF) in JMML may be informative.

Original languageEnglish (US)
Pages (from-to)579-585
Number of pages7
JournalAmerican Journal of Hematology
Volume86
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint Dive into the research topics of 'Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype'. Together they form a unique fingerprint.

  • Cite this